Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Refractory Status Epilepticus Clear all
Terminated Not applicable Interventional

Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus

NCT05934903
View directory record Official record
Conditions
Status Epilepticus, Refractory Status Epilepticus
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Refractory Status Epilepticus

NCT00265616
View directory record Official record
Conditions
Status Epilepticus
Interventions
propofol, thiopental/pentobarbital
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

NCT02052739
View directory record Official record
Conditions
Super-refractory Status Epilepticus
Interventions
SAGE-547
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • Sarasota, Florida • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Not applicable Interventional Results available

Repeated TMS at Low Frequencies to Reduce Seizure Occurrence

NCT03154307
View directory record Official record
Conditions
Epilepsy, Status Epilepticus, Epilepsia Partialis Continua, Epilepsia Partialis Continua, Refractory (Medically)
Interventions
Low frequency repeated TMS (LF-rTMS)
Device
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 4 Interventional

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

NCT05684978
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Perampanel
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Not yet recruiting Phase 4 Interventional

Ketamine for the Treatment of Refractory Status Epilepticus

NCT07177235
View directory record Official record
Conditions
Refractory Status Epilepticus
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

NCT05851391
View directory record Official record
Conditions
Hypoxia-Ischemia, Brain, Heart Arrest, Status Epilepticus, Refractory Status Epilepticus, Seizures, Anoxic-Ischemic Encephalopathy, Anoxia-Ischemia, Cerebral
Interventions
Burst Suppression EEG Target Intravenous Anesthesia, Seizure Suppression EEG Target Intravenous Anesthesia
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Not applicable Interventional

Ketogenic Diet for Refractory Status Epilepticus

NCT01796574
View directory record Official record
Conditions
Status Epilepticus, Seizure, Epilepsy, Refractory Status Epilepticus, Medically Resistant Status Epilepticus
Interventions
Ketogenic diet
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Phoenix, Arizona • Honolulu, Hawaii • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Not yet recruiting Phase 3 Interventional

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

NCT07281027
View directory record Official record
Conditions
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
Anakinra, Tocilizumab, Standard medical treatment
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
2 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 10:45 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus

NCT03115489
View directory record Official record
Conditions
Refractory Epilepsy
Interventions
Traditional Treatment (Group T), Ketamine Infusion (Group K)
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Study With SAGE-547 for Super-Refractory Status Epilepticus

NCT02477618
View directory record Official record
Conditions
Super-Refractory Status Epilepticus
Interventions
SAGE-547, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
100
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 22, 2026, 10:45 AM EDT
Withdrawn Phase 3 Interventional

Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

NCT02726867
View directory record Official record
Conditions
Epilepsy, Status Epilepticus
Interventions
levetiracetam, lacosamide, Ketamine, Phenobarbital
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Jul 22, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Established Status Epilepticus Treatment Trial

NCT01960075
View directory record Official record
Conditions
Benzodiazepine Refractory Status Epilepticus
Interventions
Fosphenytoin, Levetiracetam, Valproic acid
Drug
Lead sponsor
University of Virginia
Other
Eligibility
2 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
65
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jul 22, 2026, 10:45 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

NCT04378075
View directory record Official record
Conditions
Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
Interventions
Vatiquinone, Placebo
Drug · Other
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Up to 20 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
San Diego, California • Stanford, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 22, 2026, 10:45 AM EDT